Vivanza Biosciences Limited has filed its mandatory annual disclosure under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations 2011 for the financial year ended March 31, 2026. The disclosure was submitted to BSE Limited on April 9, 2026, in compliance with Regulation 31(4) requirements.

Promoter Shareholding Details

The disclosure reveals the shareholding positions of the company's promoters as of March 31, 2026. Both promoters have confirmed their holdings and declared no encumbrance activities during the financial year.

Regulatory Compliance

The annual disclosure under Regulation 31(4) of SEBI SAST Regulations 2011 is a mandatory requirement for promoters of listed companies. This regulation ensures transparency in shareholding patterns and any changes in substantial acquisitions or disposals by promoters.

Key compliance highlights include:

• Filing Date: April 9, 2026
• Reporting Period: Financial Year ended March 31, 2026
• Regulatory Framework: SEBI (SAST) Regulations 2011
• Declaration: No encumbrance of shares by either promoter during FY26

Company Information

Vivanza Biosciences Limited, incorporated in 1982, operates from its registered office in Ahmedabad, Gujarat. The company is led by Managing Director Jayendra Mehta, who signed the disclosure filing on behalf of the company. The filing confirms the company's commitment to maintaining regulatory compliance and transparency in its shareholding disclosures.

Both promoters submitted individual declarations confirming their respective shareholdings and stating that no direct or indirect encumbrance of shares occurred during the financial year ended March 31, 2026.

Vivanza Biosciences Limited has formally notified BSE Limited regarding its non-applicability under the "Large Corporate" category as defined by regulatory circulars. The company confirmed that it does not meet the criteria for Large Corporate classification as of March 31, 2026.

Regulatory Compliance Confirmation

The company's communication to BSE Limited, dated April 9, 2026, specifically addresses compliance requirements under multiple regulatory frameworks. The confirmation relates to fund raising regulations for debt securities issuance by large corporates.

Regulatory Framework References

The company's confirmation references several key regulatory circulars that establish the framework for Large Corporate classification and associated disclosure requirements:

• SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018
• SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021 (updated April 13, 2022)
• BSE Circular No. LIST/COMP/05/2019-20 dated April 11, 2019
• BSE Circular No. LIST/COMP/59/2019-20 dated March 3, 2020
• BSE Notice No. 20220427-2 dated April 27, 2022

Disclosure Exemption Impact

Based on its non-Large Corporate status, Vivanza Biosciences Limited is exempt from filing specific disclosure requirements for FY26. The exemption covers Initial Disclosure filings under Annexure A as per BSE circulars and Annexure XII A under the SEBI operational circular.

Corporate Authorization

The formal communication was digitally signed by Chaitra Arora, Company Secretary & Compliance Officer, on April 9, 2026. The company has requested BSE Limited to take this confirmation on record for regulatory compliance purposes.